Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype
View Patent ↗Polymorphisms in the FLAP and LTA4H gene are shown by genetic association analysis to be susceptibility markers for myocardial infarction (MI) and ACS, as well as stroke and PAOD. Pathway targeting for treatment and diagnostic applications in identifying those who are at risk of developing MI, ACS, stroke or PAOD, in particular are described. The invention also provides methods of prophylaxis therapy for MI in human subjects having a race including black African ancestry by administering to the subject a composition comprising a therapeutically effective amount of MI therapeutic agent that inhibits leukotriene synthesis in vivo. The invention also provides for compositions comprising a leukotriene synthesis inhibitor and a statin and methods of using these compositions to reduce C-reactive protein in a human subject at risk of MI, ACS, stroke and/or PAOD.
1. A method of detecting an LTA 4 H haplotype associated with myocardial infarction (MI) risk in a human individual and assessing susceptibility to MI in said human individual, comprising
assaying a nucleic acid-containing sample obtained from the human individual to detect therein the presence of an LTA 4 H haplotype associated with MI risk, wherein the LTA 4 H haplotype comprises polymorphisms SG12S16 having allele C, SG12S21 having allele G, SG12S23 having allele T, SG12S25 having allele A, SG12S26 having allele T, SG12S100 having allele T, SG12S28 having allele T, SG12S143 having allele C, SG12S144 having allele G, and SG12S221 having allele G,
wherein the presence of the LTA 4 H haplotype in the nucleic acid-containing sample identifies the individual as having elevated susceptibility to MI.